Management of local recurrence after radical nephrectomy: surgical removal with or without systemic treatment is still the gold standard. Results from a multicenter international cohort.

Published on Aug 21, 2021in International Urology and Nephrology1.843
· DOI :10.1007/S11255-021-02966-9
Michele Marchioni15
Estimated H-index: 15
(University of Chieti-Pescara),
Petros Sountoulides17
Estimated H-index: 17
+ 9 AuthorsAlessandro Antonelli30
Estimated H-index: 30
(University of Verona)
OBJECTIVE To evaluate the survival outcomes of patients with local recurrence after radical nephrectomy (RN) and to test the effect of surgery, as monotherapy or in combination with systemic treatment, on cancer-specific mortality (CSM). METHODS Patients with local recurrence after RN were abstracted from an international dataset. The primary outcome was CSM. Cox's proportional hazard models tested the main predictors of CSM. Kaplan-Meier method estimates the 3-year survival rates. RESULTS Overall, 96 patients were included. Of these, 44 (45.8%) were metastatic at the time of recurrence. The median time to recurrence after RN was 14.5 months. The 3-year cancer-specific survival rates after local recurrence were 92.3% (± 7.4%) for those who were treated with surgery and systemic therapy, 63.2% (± 13.2%) for those who only underwent surgery, 22.7% (± 0.9%) for those who only received systemic therapy and 20.5% (± 10.4%) for those who received no treatment (p < 0.001). Receiving only medical treatment (HR: 5.40, 95% CI 2.06-14.15, p = 0.001) or no treatment (HR: 5.63, 95% CI 2.21-14.92, p = 0.001) were both independently associated with higher CSM rates, even after multivariable adjustment. Following surgical treatment of local recurrence 8 (16.0%) patients reported complications, and 2/8 were graded as Clavien-Dindo ≥ 3. CONCLUSIONS Surgical treatment of local recurrence after RN, when feasible, should be offered to patients. Moreover, its association with a systemic treatment seems to warrantee adjunctive advantages in terms of survival, even in the presence of metastases.
#1Bryan Dr Hall (UW: University of Wisconsin-Madison)H-Index: 1
#2Edwin Jason Abel (UW: University of Wisconsin-Madison)H-Index: 5
Surgical metastasectomy continues to be utilized for patients with solitary or low-volume metastatic renal cell carcinoma (mRCC). Although few high-quality data are available to evaluate outcomes, local treatment is recommended when feasible because it may allow a subset of patients to delay or avoid systemic treatments. With the development of improved mRCC therapies, utilization of metastasectomy has increased because most patients have incomplete responses to systemic treatment of their metas...
2 CitationsSource
#1Sara Omid (Medical University of Vienna)H-Index: 1
#2Mohammad Abufaraj (Medical University of Vienna)H-Index: 18
Last. Mesut Remzi (Medical University of Vienna)H-Index: 35
view all 3 authors...
PURPOSE OF REVIEW The role of metastasectomy in the management of metastatic renal cell carcinoma (mRCC) remains controversial. The aim of this review is to summarize and evaluate the recent findings about the surgical treatment of patients with mRCC focusing on the literature published in the last 2 years. RECENT FINDINGS Despite the lack of randomized controlled trials, the benefit of metastasectomy in term of cancer-specific and overall survival have been demonstrated in large observational s...
2 CitationsSource
#1Eduard Roussel (Katholieke Universiteit Leuven)H-Index: 3
#2Riccardo Campi (UniFI: University of Florence)H-Index: 17
Last. Maarten Albersen (Katholieke Universiteit Leuven)H-Index: 26
view all 33 authors...
Abstract Background Cytoreductive nephrectomy (CN) plays an important role in the treatment of a subgroup of metastatic renal cell carcinoma (mRCC) patients. Objective We aimed to evaluate morbidity associated with this procedure and identify potential predictors thereof to aid patient selection for this procedure and potentially improve patient outcomes. Design, setting, and participants Data from 736 mRCC patients undergoing CN at 14 institutions were retrospectively recorded in the Registry f...
5 CitationsSource
BACKGROUND: In order to improve standard reporting of outcomes after partial nephrectomy, different "trifecta" systems have been conceived. The subjective assessment of the included parameters and the unreliability for off-clamp procedures limited their reproducibility; their role in predicting functional and oncologic outcomes has never been assessed. We propose a new trifecta, based on standardized parameters, that summarizes PN outcomes regardless the clamping technique used and predicts main...
9 CitationsSource
#1Agustin Romeo (Hospital Italiano de Buenos Aires)H-Index: 2
#2Patricio García Marchiñena (Hospital Italiano de Buenos Aires)H-Index: 4
Last. Guillermo Gueglio (Hospital Italiano de Buenos Aires)H-Index: 6
view all 4 authors...
Abstract Introduction and objectives Kidney cancers represent 2% of cancers worldwide; the most common type is renal clear cell carcinoma (RCC). Surgical treatment remains the only effective therapy for localized renal cell carcinoma. Approximately 20% to 38% of patients undergoing radical nephrectomy (RN) for localized RCC will have subsequent disease progression, with 0.8% to 3.6% of local recurrences within the ipsilateral retroperitoneum (RFR). The main objective of this study is to evaluate...
7 CitationsSource
#1Rebecca L. Siegel (ACS: American Cancer Society)H-Index: 67
#2Kimberly D. Miller (ACS: American Cancer Society)H-Index: 28
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 139
view all 3 authors...
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2016) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2017) were collected by the National Center for Health Statis...
7,306 CitationsSource
#1Saeed Dabestani (Lund University)H-Index: 19
#2Christian Beisland (University of Bergen)H-Index: 16
Last. Axel Bex (NKI-AVL: Netherlands Cancer Institute)H-Index: 54
view all 20 authors...
Abstract Background Optimal follow-up (FU) strategy to detect potentially curable (PC) recurrences after treatment of localised clear cell renal cell carcinoma (ccRCC) is unclear. This study retrospectively analysed a large international database to determine recurrence patterns and overall survival (OS), as part of a wider project to issue recommendations on FU protocols. Objective To analyse associations between RCC recurrences in patients with ccRCC, their risk group stratifications, treatmen...
35 CitationsSource
#1Géraldine PignotH-Index: 1
#2Yohann Loriot (French Institute of Health and Medical Research)H-Index: 10
Last. Elizabeth R. Plimack (Fox Chase Cancer Center)H-Index: 15
view all 5 authors...
Abstract Context Management of metastatic genitourinary malignancies has recently been transformed through the use of immune checkpoint inhibitors. The best way to integrate them into local treatment paradigms is still under investigation. Objective To systematically evaluate evidence regarding the use of immunotherapy in the treatment of local disease, in both the perioperative and the metastatic setting. Evidence acquisition We performed a critical review of PubMed and accor...
16 CitationsSource
#2Riccardo Bertolo (Cleveland Clinic)H-Index: 26
Last. Umberto Capitanio (UniSR: Vita-Salute San Raffaele University)H-Index: 62
view all 12 authors...
Abstract Context Management of locally recurrent renal cancer is complex. Objective In this systematic review we analyse the available literature on the management of local renal cancer recurrence. Evidence acquisition A systematic search (PubMed, Web of Science, CINAHL, Clinical Trials, and Scopus) of English literature from 2000 to 2017 was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Evidence synthesis The search identified 1838 art...
10 CitationsSource
#1Roderick de Bruijn (NKI-AVL: Netherlands Cancer Institute)H-Index: 6
#2Teele Kuusk (NKI-AVL: Netherlands Cancer Institute)H-Index: 10
Last. Axel Bex (NKI-AVL: Netherlands Cancer Institute)H-Index: 54
view all 8 authors...
Objective To determine the time-to-targeted therapy (TTT) in patients with not completely resected low-volume oligometastatic disease who were observed following debulking cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC). Methods Patients with synchronous mRCC with not completely resected low-volume metastases and in whom observation after CN was a multidisciplinary tumor board recommendation were identified from an approved institutional database. Patient data, Internat...
4 CitationsSource
Cited By0